Serina Therapeutics, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded no revenue for the third quarter, a decrease from $14,000 in the same period last year. For the nine months ended September 30, 2025, total revenues were $130,000, up from $70,000 in the prior year. The company’s operating expenses increased to $6.4 million for the third quarter, compared to $5.3 million in the same quarter of 2024, and totaled $17.9 million for the nine-month period, up from $11.6 million in 2024. This resulted in a net loss of $4.6 million for the third quarter and $15.9 million for the nine months, compared to a net income of $1.4 million and a loss of $8.5 million, respectively, in the prior year.
The company’s financial position has changed markedly since the previous fiscal period, with cash and cash equivalents rising to $8.6 million as of September 30, 2025, compared to $3.7 million at the end of 2024. This increase was primarily due to financing activities, including a $4.9 million private placement of Series A Convertible Preferred Stock and proceeds from the exercise of warrants. However, total liabilities also increased significantly to $10.8 million from $6.2 million, driven by higher accounts payable and accrued expenses.
Strategically, Serina Therapeutics has focused on advancing its clinical-stage pipeline, particularly its lead product candidate, SER-252, which is intended for the treatment of advanced Parkinson’s disease. The company has engaged in partnerships, including a collaboration with Enable Injections, to enhance the delivery of SER-252. However, the company announced a clinical hold on its Investigational New Drug (IND) application for SER-252 due to FDA requests for additional information regarding a formulation excipient, which could delay its development timeline.
Operationally, Serina Therapeutics has expanded its workforce and established a new subsidiary in Australia to support clinical research activities. The company’s employee headcount has increased, reflecting its commitment to advancing its research and development efforts. Despite these developments, the company continues to face substantial doubt regarding its ability to continue as a going concern, as it has historically incurred significant losses and expects to require additional capital to fund ongoing operations and product development.
Looking ahead, Serina Therapeutics anticipates continued increases in research and development expenses as it progresses through clinical trials and seeks regulatory approvals for its product candidates. The company plans to finance its operations through equity offerings, debt financing, and potential collaborations. However, it acknowledges the uncertainty surrounding its ability to raise sufficient capital and the potential impact on its business strategy and operational plans.
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc. is a clinical-stage biotechnology company developing proprietary polymer-based drug delivery technologies, primarily its POZ platform, to improve the efficacy and safety of therapeutics. The company focuses on CNS disorders, notably Parkinson’s disease, with drug candidates designed for continuous delivery of dopamine agonists via subcutaneous injection. Serina’s platform enables enhanced drug loading, controlled release, and reduced immunogenicity, targeting pharmaceutical developers and patients through internal development and partnerships.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.